105.19USD+3.82%Mkt Cap: 1.57B USDP/E: —Last update: 2026-05-26
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.57B USD
Enterprise Value1.64B USD
Revenue (TTM)1.30M USD
Gross Profit-100.07M USD
Net Income (TTM)-140.06M USD
Revenue/Share0.0840 USD
Last Price105.19 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees109
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-39.63
PEG—
EV/EBITDA-13.60
EV/Revenue1262.64
P/S1247.84
P/B201.77
EPS (TTM)-8.39
EPS (Forward)-2.79
52W Range
12.2465% of range155.29
52W High155.29 USD
52W Low12.24 USD
Profitability
Gross Margin0.00%
Oper. Margin-9465.46%
EBITDA Margin0.00%
Profit Margin-10773.46%
ROE-1752.22%
ROA-95.62%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-129.79M USD
CapEx (TTM)31.00K USD
FCF Margin-6854.45%
FCF Yield-5.66%
Net Debt19.24M USD
Net Debt/EBITDA-0.16
Balance Sheet
Debt/Equity13.39
Current Ratio6.46
Quick Ratio6.11
Book Value/Sh0.5480 USD
Cash/Share11.02 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)277.50 USD
Target Range230.00 USD – 325.00 USD
# Analysts2
Ownership
Shares Out.14.67M
Float7.86M
Insiders23.16%
Institutions82.93%
Short Interest
Short Ratio5.8d
Short % Float25.05%
Short % Out.18.71%
Shares Short2.73M
Short (prev mo.)2.12M
Technical
SMA 5093.09 (+13.0%)
SMA 20068.30 (+54.0%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)592.99K
Avg Vol (10d)630.03K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—